Becton, Dickinson and Company (BDX) have seen a spectrum of financial outcomes recently. The company's board has declared dividends and authorized a 10 Million additional share repurchase, completing $750 Million repurchases in Fiscal Year 2025 so far. However, with several downgrades from Citigroup, potential tariffs affecting profits, and missed growth targets have led to a downgrade by BofA. The unveiling of an Advanced Cell Analyzer with spectral and imaging innovations illustrates BDX's commitment to advancing health care technology. Furthermore, BDX has completed an important acquisition from Edwards Lifesciences and is planning to separate from its Bioscience and Diagnostic Solutions Business. Several quarterly earnings show strength in EPS growth despite a revenue miss for Q2 2025. Despite some negative outcomes, the potential value and innovation within the company are recognized, and Joseph Cusack has been named President of BD Urology and Critical Care.
Becton Dickinson and BDX News Analytics from Thu, 01 Aug 2024 07:00:00 GMT to Thu, 22 May 2025 18:45:00 GMT -
Rating -5
- Innovation 4
- Information 7
- Rumor 2
